www.bloomberg.com
The highly effective weight-loss drug semaglutide, marketed as Wegovy and Ozempic, is expanding its global availability, with approvals moving forward in countries like Japan and Australia. However, as the drug becomes more accessible, supply shortages remain a persistent challenge in many regions. Authorities are also increasing scrutiny regarding potential safety risks, including rare cases of suicidal ideation, and weighing long-term economic impacts on healthcare systems, as the high cost and required sustained use raise questions about affordability and insurance coverage.
Read More
